This is a summary of the European public assessment report (EPAR) for Fosavance. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Fosavance. If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).
Therapeutic Indication
### Therapeutic indication Treatment of postmenopausal osteoporosis in patients at risk of vitamin-D insufficiency. Fosavance reduces the risk of vertebral and hip fractures.
Therapeutic Area (MeSH)
N/AATC Code
M05BB03
ATC Item
alendronic acid and colecalciferol
Pharmacotherapeutic Group
Drugs for treatment of bone diseases
Active Substance (Summary)
N/AINN / Common Names
N/AEMA Name
Fosavance
Medicine Name
Fosavance
Aliases
N/ANo risk management plan link.
